Olema Pharmaceuticals (OLMA) Operating Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Operating Expenses data on file, last reported at $58.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $58.0 million, up 66.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $201.8 million (up 41.33% YoY), and the FY2025 annual result was $178.7 million, up 25.62% from the prior year.
• Operating Expenses rose to $58.0 million in Q1 2026 per OLMA's latest filing, from $50.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $58.0 million in Q1 2026 and troughed at $21.6 million in Q2 2023.
• A 5-year average of $34.8 million and a median of $33.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 101.51% in 2022, then tumbled 35.12% in 2023.
• A 5-year view of Operating Expenses shows it stood at $27.2 million in 2022, then advanced by 11.75% to $30.4 million in 2023, then gained by 20.88% to $36.8 million in 2024, then surged by 36.22% to $50.1 million in 2025, then climbed by 15.78% to $58.0 million in 2026.
• Business Quant data shows OLMA's Operating Expenses at $58.0 million in Q1 2026, $50.1 million in Q4 2025, and $45.9 million in Q3 2025.